See more : ISM Resources Corp. (ISMRF) Income Statement Analysis – Financial Results
Complete financial analysis of BioLargo, Inc. (BLGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLargo, Inc., a leading company in the Chemicals industry within the Basic Materials sector.
You may be interested
- Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO) Income Statement Analysis – Financial Results
- Beijing Roborock Technology Co., Ltd. (688169.SS) Income Statement Analysis – Financial Results
- IZMO Limited (IZMO.BO) Income Statement Analysis – Financial Results
- Clearford Water Systems Inc. (CLIRF) Income Statement Analysis – Financial Results
- Sondotécnica Engenharia de Solos S.A. (SOND5.SA) Income Statement Analysis – Financial Results
BioLargo, Inc. (BLGO)
About BioLargo, Inc.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.23M | 5.88M | 2.53M | 2.43M | 1.86M | 1.36M | 516.21K | 281.11K | 127.58K | 111.55K | 167.95K | 65.54K | 156.19K | 156.76K | 138.13K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 749.84K | 833.54K | 1.88M | 2.39M | 1.93M | 2.50M | 1.30M | 4.50M | 7.70M | 9.40M | 9.80M | 6.70M |
| Cost of Revenue | 6.08M | 3.03M | 1.43M | 1.20M | 945.00K | 743.00K | 322.72K | 105.88K | 62.07K | 56.00K | 29.66K | 39.78K | 44.76K | 125.48K | 114.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.29K | 0.00 | 119.41K | 119.18K | 22.41K | 0.00 | 0.00 | 0.00 | 0.00 | 5.10M | 6.40M | 7.80M | 7.70M | 5.20M |
| Gross Profit | 6.15M | 2.86M | 1.10M | 1.23M | 916.00K | 621.00K | 193.50K | 175.23K | 65.52K | 55.55K | 138.29K | 25.76K | 111.43K | 31.28K | 23.58K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | -20.29K | 0.00 | 630.43K | 714.35K | 1.86M | 2.39M | 1.93M | 2.50M | 1.30M | -600.00K | 1.30M | 1.60M | 2.10M | 1.50M |
| Gross Profit Ratio | 50.32% | 48.56% | 43.58% | 50.49% | 49.22% | 45.53% | 37.48% | 62.34% | 51.35% | 49.80% | 82.34% | 39.30% | 71.34% | 19.95% | 17.07% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.08% | 85.70% | 98.81% | 100.00% | 100.00% | 100.00% | 100.00% | -13.33% | 16.88% | 17.02% | 21.43% | 22.39% |
| Research & Development | 2.28M | 1.32M | 1.37M | 1.34M | 1.47M | 1.72M | 1.63M | 1.38M | 684.55K | 642.92K | 742.25K | 126.02K | 99.50K | 100.56K | 170.12K | 113.75K | 131.35K | 129.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 6.14M | 5.26M | 4.43M | 0.00 | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 246.00K | 246.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.06M | 6.73M | 6.17M | 7.47M | 6.14M | 5.26M | 4.43M | 3.71M | 3.55M | 2.79M | 2.00M | 4.61M | 3.17M | 4.12M | 3.96M | 4.83M | 2.99M | 1.63M | 944.81K | 971.94K | 2.34M | 2.16M | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -74.00K | -55.00K | -137.00K | -218.00K | 73.00K | 71.13K | 13.74K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | 0.00 | 0.00 | 0.00 | 8.55K | -661.87K | 3.45M | 268.46K | -1.32M | 258.13K | 186.53K | 189.35K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.34M | 7.98M | 7.48M | 8.67M | 7.39M | 6.88M | 6.09M | 5.11M | 4.25M | 3.45M | 2.76M | 4.74M | 3.27M | 4.23M | 5.25M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.35M | 1.50M | 7.42M | 2.86M | 453.95K | 1.99M | 1.87M | 1.57M | 1.20M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Cost & Expenses | 16.42M | 11.00M | 8.91M | 9.88M | 8.34M | 7.62M | 6.41M | 5.22M | 4.31M | 3.50M | 2.79M | 4.78M | 3.32M | 4.36M | 5.36M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.37M | 1.50M | 7.54M | 2.98M | 476.36K | 1.99M | 1.87M | 1.57M | 1.20M | 6.50M | 8.00M | 9.40M | 8.80M | 5.70M |
| Interest Income | 0.00 | 53.00K | 234.00K | 1.92M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135.53K | 35.96K | 0.00 | 153.51K | 0.00 | 255.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 91.00K | 53.00K | 234.00K | 1.92M | 4.00M | 3.49M | 3.86M | 3.13M | 994.67K | 348.15K | 281.59K | 616.35K | 793.26K | 1.67M | 1.63M | 1.15M | 1.56M | 344.88K | 242.49K | 250.70K | 344.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 45.00K | 20.00K | 58.00K | 65.00K | 50.00K | 29.84K | 15.89K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | -796.55K | 246.10K | -4.60K | 660.30K | 9.94K | 176.10K | 268.46K | 197.19K | 258.13K | 186.53K | 189.35K | -100.00K | -300.00K | -100.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.19M | -5.10M | -6.70M | -7.83M | -7.44M | -7.23M | -5.73M | -4.93M | -4.07M | -3.38M | -2.61M | -4.71M | -3.15M | -4.19M | -4.11M | -5.00M | -3.05M | -2.56M | -698.70K | -967.34K | -1.71M | -1.54M | -2.77M | -4.46M | 1.60M | 664.46K | 245.16K | 1.12M | -100.00K | -2.30M | -400.00K | -200.00K | 1.00M | 1.00M |
| EBITDA Ratio | -34.23% | -85.16% | -248.83% | -299.22% | -341.21% | -449.49% | -1,136.19% | -1,749.86% | -3,346.62% | -3,030.56% | -1,553.32% | -7,189.59% | -2,018.88% | -2,751.20% | 3,370.18% | 0.00% | -3,918.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -881.77% | -225.65% | 246.39% | 27.78% | 12.68% | 44.96% | -7.69% | -51.11% | -5.19% | -2.13% | 10.20% | 14.93% |
| Operating Income | -4.19M | -5.12M | -6.38M | -7.45M | -6.48M | -6.41M | -5.90M | -4.93M | -4.18M | -3.39M | -2.62M | -4.72M | -3.16M | -4.20M | -14.01M | -6.05M | -3.78M | -1.76M | -944.81K | -971.94K | -2.37M | -1.50M | -6.79M | -2.15M | -112.29K | 406.32K | 58.63K | 935.07K | 100.00K | -2.00M | -300.00K | -200.00K | 1.00M | 1.00M |
| Operating Income Ratio | -34.23% | -87.00% | -252.11% | -306.17% | -348.09% | -470.09% | -1,141.98% | -1,755.52% | -3,277.49% | -3,040.35% | -1,559.82% | -7,197.88% | -2,023.91% | -2,678.33% | -10,138.78% | 0.00% | -4,730.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -905.25% | -257.85% | -5.98% | 16.99% | 3.03% | 37.39% | 7.69% | -44.44% | -3.90% | -2.13% | 10.20% | 14.93% |
| Total Other Income/Expenses | -449.00K | 61.00K | -458.00K | -2.12M | -4.74M | -4.28M | -3.65M | -3.14M | -895.55K | -348.15K | -281.59K | -616.35K | -793.26K | -1.54M | -8.76M | 59.99K | -1.48M | 796.55K | -246.10K | -246.10K | -344.83K | 6.74K | 121.94K | 35.96K | -1.41M | 153.51K | 222.88K | 255.93K | 200.00K | 200.00K | 100.00K | 300.00K | 0.00 | -1.00M |
| Income Before Tax | -4.64M | -5.13M | -6.89M | -9.70M | -11.44M | -10.70M | -9.55M | -8.07M | -5.08M | -3.74M | -2.90M | -5.33M | 0.00 | -4.07M | -22.77M | -5.99M | -5.26M | -965.82K | -1.19M | -1.22M | -2.71M | -1.49M | -6.65M | -2.11M | -1.52M | 559.83K | 281.51K | 1.19M | 300.00K | -1.80M | -200.00K | 300.00K | 0.00 | 0.00 |
| Income Before Tax Ratio | -37.90% | -87.22% | -272.38% | -398.85% | -614.72% | -784.16% | -1,849.34% | -2,872.35% | -3,979.42% | -3,352.46% | -1,727.49% | -8,138.27% | 0.00% | -2,599.36% | -16,482.26% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.54% | -80.78% | 23.40% | 14.56% | 47.62% | 23.08% | -40.00% | -2.60% | 3.19% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | -636.00K | 483.00K | 766.00K | 3.31M | -790.00K | 3.43M | 2.89M | 874.50K | -47.45K | -372.92K | 0.00 | 793.26K | 1.54M | 10.39M | 1.09M | 1.48M | 344.88K | -3.61K | 250.70K | 4.91M | 3.44M | 0.00 | 3.47K | -11.54K | 196.71K | 103.68K | 554.64K | -100.00K | -100.00K | -100.00K | 100.00K | -1.00M | -900.00K |
| Net Income | -3.50M | -4.50M | -7.38M | -10.47M | -14.75M | -10.22M | -9.12M | -7.84M | -5.06M | -3.69M | -2.53M | -5.33M | -3.95M | -5.74M | -15.61M | -7.14M | -5.26M | -1.31M | -1.19M | -1.22M | -7.62M | -4.94M | -6.65M | -2.12M | -1.51M | 531.12K | 261.83K | 968.36K | -300.00K | -1.70M | -100.00K | 200.00K | 1.00M | 900.00K |
| Net Income Ratio | -28.65% | -76.41% | -291.47% | -430.35% | -792.53% | -749.34% | -1,766.19% | -2,788.89% | -3,962.92% | -3,309.92% | -1,505.44% | -8,138.27% | -2,531.80% | -3,663.12% | -11,302.54% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.96% | -80.16% | 22.20% | 13.54% | 38.72% | -23.08% | -37.78% | -1.30% | 2.13% | 10.20% | 13.43% |
| EPS | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| Weighted Avg Shares Out | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
| Weighted Avg Shares Out (Dil) | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
BioLargo says peer-reviewed scientific paper confirms safety of water treated by its Advanced Oxidation System
BioLargo Inc (OTCQB:BLGO) has announced the publication of a peer-reviewed scientific paper that confirms the safety of water treated by its Advanced Oxidation System (AOS), an energy-efficient industrial water disinfection technology. The Westminster, California-based company said the paper, which focused...
Peer-Reviewed Scientific Paper Confirms Safety of Water Treated by BioLargo's Advanced Oxidation System
Study demonstrates AOS generates less disinfection by-products than common wastewater treatment technologies WESTMINSTER, CA / ACCESSWIRE / June 21, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced the publication of a peer-reviewed...
BioLargo (BLGO) to Present at LD Micro Invitational XI
Presentation on Wednesday, June 9 at 5:00 PM ET WESTMINSTER, CA / ACCESSWIRE / June 4, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it will be giving an investor...
BioLargo strengthens balance sheet by eliminating nearly all of its convertible debt
BioLargo Inc (OTCQB:BLGO) reports that it has eliminated nearly all of its convertible debt to strengthen its balance sheet. The company paid off $406,000 in convertible debt that would have come due in August 2021, through cash and equity.
BioLargo Strengthens its Balance Sheet by Eliminating Convertible Debt to Position Company for Growth
WESTMINSTER, CA / ACCESSWIRE / May 24, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it has eliminated nearly all of its convertible debt. The announcement comes as a result...
BioLargo seeking 'to make life better' when it comes to clean water, clean air, and health
Targets solid waste, wastewater, industrial odor, advanced wound-care and distinfectant markets Clyra Medical unit has applied its technology to the coronavirus pandemic with public sales of its disinfectant spray Flagship product CupriDyne Clean marketed to cannabis producers seeking odor elimination Working with US EPA to...
BioLargo reports improving balance sheet as it plans first commercial pilots for its PFAS-treatment technology
BioLargo Inc (OTCQB:BLGO), a developer of sustainable cleantech technologies, says its balance sheet is improving. In addition, the California-based company also said that it is working with prospective partners to plan and schedule as soon as possible the first commercial...
BioLargo Q1 2021 Quarterly Report Highlights Improving Balance Sheet and Status of PFAS Commercial Pilots in Emerging Multi-Billion Dollar Market
Investor Webcast Scheduled for Wednesday, May 19, 2021 at 4:30pm ET WESTMINSTER, CA / ACCESSWIRE / May 17, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q...
BioLargo (BLGO) Q1 2021 Earnings Webcast and Conference Call Wednesday, May 19, 2021 - 4:30 PM Eastern Time
WESTMINSTER, CA / ACCESSWIRE / May 12, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT...
From Clean Air to Clean Water, BioLargo Aims to be a Leader in Cleantech
BioLargo, Inc. (OTCQB: BLGO) is a small but mighty full-service environmental engineering company with a vision of becoming one of the foremost thought leaders in cleantech products and services. The company's mission is to invent, develop and commercialize innovative platform...
Source: https://incomestatements.info
Category: Stock Reports